Gyre Therapeutics (NASDAQ:GYRE) Rating Lowered to Hold at Wall Street Zen

Gyre Therapeutics (NASDAQ:GYRE) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday.

A number of other research analysts also recently issued reports on GYRE. Zacks Research upgraded shares of Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, November 14th. Weiss Ratings reiterated a “sell (d)” rating on shares of Gyre Therapeutics in a research report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $17.00.

Gyre Therapeutics Price Performance

Shares of GYRE opened at $7.55 on Friday. The business has a 50-day moving average of $7.96 and a 200-day moving average of $7.78. The company has a market capitalization of $727.29 million, a price-to-earnings ratio of 755.76 and a beta of 1.97. Gyre Therapeutics has a 1 year low of $6.11 and a 1 year high of $12.62.

Gyre Therapeutics (NASDAQ:GYRE) last announced its earnings results on Thursday, March 12th. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.04). The company had revenue of $37.20 million during the quarter, compared to the consensus estimate of $36.30 million. Gyre Therapeutics had a net margin of 4.31% and a return on equity of 11.25%.

Institutional Investors Weigh In On Gyre Therapeutics

Large investors have recently added to or reduced their stakes in the business. Barclays PLC increased its holdings in Gyre Therapeutics by 38.3% in the fourth quarter. Barclays PLC now owns 18,531 shares of the company’s stock worth $131,000 after purchasing an additional 5,135 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Gyre Therapeutics by 37.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company’s stock worth $1,194,000 after buying an additional 45,772 shares in the last quarter. State Street Corp boosted its holdings in shares of Gyre Therapeutics by 10.7% during the 4th quarter. State Street Corp now owns 202,225 shares of the company’s stock worth $1,428,000 after buying an additional 19,472 shares in the last quarter. Wells Fargo & Company MN grew its position in shares of Gyre Therapeutics by 132.4% during the 4th quarter. Wells Fargo & Company MN now owns 12,919 shares of the company’s stock worth $91,000 after buying an additional 7,361 shares during the period. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of Gyre Therapeutics during the 4th quarter worth approximately $77,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.